How to access Wainua from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient diagnosed with hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy may receive a prescription for Wainua (eplontersen) from their treating neurologist, often in coordination with a multidisciplinary amyloid service in Abu Dhabi, Dubai, or Sharjah. Wainua is FDA-approved for this indication and is developed by Ionis and Sobi. It is a newer-generation ligand-conjugated antisense oligonucleotide (ASO) designed to improve on the earlier ASO generation. Wainua is not routinely stocked through the UAE domestic supply chain for this indication, so access typically runs through the named-patient import pathway.
This guide explains the legal pathway, the documentation your neurologist prepares, typical timing, indicative cost posture, and where Reserve Meds fits in.
The clinical situation
Wainua is a subcutaneous ligand-conjugated antisense oligonucleotide that silences hepatic TTR production. It is self-administered (or caregiver-administered) monthly by subcutaneous auto-injector after in-clinic training — a meaningful step up in convenience relative to weekly injections, and without the REMS-level platelet monitoring programme of the earlier ASO generation. Routine labs still matter (vitamin A supplementation, periodic platelet and renal panels), but the monitoring cadence is closer to other monthly specialty injectables. Eligibility requires genetic confirmation of a pathogenic TTR variant, symptomatic polyneuropathy, and a cardiac workup to characterise any ATTR-CM overlap. Your neurologist will establish baseline NIS+7, polyneuropathy disability score, and baseline labs.
Is Wainua legally importable into the UAE?
Yes — through the UAE Ministry of Health and Prevention (MoHAP) named-patient import framework, with parallel authority operated by the Department of Health (DoH) in Abu Dhabi and the Dubai Health Authority (DHA) in Dubai depending on where the prescribing facility sits.
The named-patient mechanism permits a UAE-licensed physician to import a medicine not locally registered when (a) it is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally available alternative suits the specific patient, (c) the physician accepts clinical responsibility, and (d) chain of custody is documented end-to-end.
How the pathway works, step by step
- Consultation with your treating neurologist. TTR genetic report, neuropathy scoring, and a clinical rationale letter.
- Baseline assessment. NIS+7, polyneuropathy disability score, cardiac workup (ECG, echocardiogram, NT-proBNP), platelet / renal / liver panels, vitamin A level.
- MoHAP named-patient application. The physician or hospital pharmacy files clinical rationale, monitoring plan, patient reference, and chain-of-custody commitment.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Wainua from authorised distribution under DSCSA.
- Cold-chain shipment. Wainua requires refrigerated handling; shipment follows validated cold-chain protocols with temperature logging.
- Arrival, dispensing, and auto-injector training. The hospital pharmacy releases product; the neurology clinic provides self-injection training and sets the monthly schedule.
What documentation your physician needs
- Clinical rationale letter confirming hATTR polyneuropathy and Wainua as the indicated therapy
- Verification of UAE medical license
- TTR genetic test result
- Baseline NIS+7 and polyneuropathy disability score
- Cardiac assessment for ATTR-CM overlap
- Baseline platelet count, renal function, liver panel, vitamin A level
- Planned dosing schedule (monthly SC auto-injector) and vitamin A supplementation plan
Reserve Meds provides a physician documentation kit bundling the templates MoHAP reviewers expect for rare-disease neurology named-patient imports.
Costs and timing
Wainua for hATTR polyneuropathy is a substantial rare-disease therapy. Reference US cash-pay for a full annual course (monthly subcutaneous auto-injector) typically sits in the high six-figure USD range. Reserve Meds operates on a drug-only reference basis and provides a transparent, itemised delivered quote — covering product, cold-chain logistics, MoHAP documentation handling, customs clearance, and concierge coordination — at the start of intake. Figures are indicative, not a binding quote until intake is complete.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 7–14 days from the moment a complete MoHAP application is submitted. Monthly refill cadence is established with the hospital pharmacy thereafter.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
- Sourcing. Through our US-licensed specialty wholesale partner under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and MoHAP / DoH / DHA review.
- Logistics. Validated cold-chain shipment to your prescribing hospital pharmacy.
- Concierge case lead. A named point of contact coordinating long-term monthly refills.
What we do not do: We are not the prescriber. We do not practise medicine. We are not the dispensing pharmacy. All clinical decisions remain with your treating neurologist. We operate on a waitlist basis during pre-launch.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP / DoH / DHA named-patient framework with appropriate documentation. See our trust and compliance page.
How is Wainua different from Tegsedi? Both are subcutaneous ASOs that silence hepatic TTR, but Wainua is ligand-conjugated, dosed monthly via auto-injector, and carries a cleaner monitoring profile than the weekly-dosed Tegsedi, which operates under a REMS programme for thrombocytopenia and glomerulonephritis. Many clinicians and families prefer Wainua's monthly cadence when both options are available.
How is Wainua different from Amvuttra? Both are monthly-to-quarterly subcutaneous therapies for hATTR polyneuropathy, but they act via different mechanisms — Wainua is an antisense oligonucleotide; Amvuttra is an siRNA. Your neurologist will select based on the clinical picture and product availability.
Will insurance cover this? Cash-pay is the default. Some UAE private insurers consider rare-disease imports case by case; we supply documentation for your submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we enter intake for Wainua coordination in the UAE.
Add me to the Wainua waitlistExamples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. We are in pre-launch; service availability is limited to our first cohort and published timelines are indicative, not guarantees. Cash-pay. Export-only (US → overseas). Composite case examples. Not medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.